Threshold incorporated; founded by George Tidmarsh

Series A financing ($9M)

Entered into an exclusive license agreement with Dr. Theodore J. Lampidis and Dr. Waldemar Priebe for a patent application covering the treatment of cancer with 2-Deoxyglucose (2DG) in combination with certain other drugs

Entered into an agreement with Baxter for the licensing and development of glufosfamide

Series B financing ($41M)

Initiated phase 1 clinical trial of 2DG with or without Taxotere for treatment of cancer

Initiated phase 2 clinical trial of Lonidamine (TH-070) for treatment of benign prostatic hyperplasia (BPH) at University of Bari, Italy

Entered into an agreement with Acraf, S.p.a., for the rights to use Acraf’s regulatory documents related to Lonidamine

Initiated phase 3 clinical trial of glufosfamide as second-line treatment of pancreatic cancer

Entered into a Development Agreement with MediBIC Co. Ltd to develop glufosfamide in various Asian countries

Received FDA Fast-Track Status for glufosfamide

Initiated phase 1/2 clinical trial of glufosfamide with gemcitabine for the first-line treatment of solid tumors, including pancreatic cancer.

Initial Public Offering (IPO) of 6.1M shares for net proceeds of $38.1M

Positive results in phase 2, single center, clinical trial of TH-070

Initiated phase 2 clinical trial of TH-070 to evaluate the dose response and safety of TH-070 for the treatment of BPH

Initiated phase 3 clinical trial of TH-070 in Europe and Canada to evaluate the safety and efficacy of TH-070 for the treatment of BPH

Follow-on public offering of 6.4M shares for net proceeds of $62.4M

Received positive results in phase 1 portion of phase 1/2 clinical trial of glufosfamide and initiated phase 2 portion of the trial

FDA placed U.S. TH-070 program on partial clinical hold due to abnormalities in liver enzymes; Voluntarily discontinued dosing in phase 3 trial in Europe and Canada

Phase 2 and 3 trials of TH-070 failed to reach primary endpoints; Discontinued development of TH-070

Completed enrollment in phase 3 and phase 2 clinical trials of glufosfamide for the treatment of pancreatic cancer

Corporate realignment, reducing workforce by approximately one-third to preserve cash and focus on multiple cancer indications with glufosfamide, 2DG and TH-302

Received Orphan Drug Designation from the FDA for glufosfamide for the treatment of pancreatic cancer

Initiated phase 2 clinical trial to evaluate the safety and efficacy of glufosfamide for the treatment of platinum-resistant ovarian cancer

Initiated phase 2 clinical trial to evaluate the safety and efficacy of glufosfamide for the treatment of recurrent, sensitive small cell lung cancer

Phase 3 trial of glufosfamide for second-line pancreatic cancer failed to reach primary endpoint

Initiated phase 2 clinical trial to evaluate the safety and efficacy of glufosfamide for the treatment of soft tissue sarcoma

Filed an Investigational New Drug Application (IND) for TH-302

Initiated phase 1 clinical trial to evaluate the safety and efficacy of TH-302 for the treatment of advanced solid tumors.

Listing of THLD common stock transferred to NASDAQ Capital Market